Predictive Oncology (DB:S1K) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

S1K Stoklara Genel Bakış

A knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies.

Şirket hakkında

S1K temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Risk Analizi

Kazançlar son 5 yılda yılda 22.4% oranında azaldı

Hisse senetleri oldukça likit değildir

Anlamlı bir piyasa değeri yok ( €25M )

Anlamlı bir geliri yok ( $1M )

+ 1 daha fazla risk

Predictive Oncology Inc. Rakipler

Geratherm Medical

XTRA:GME

€20.2m

aap Implantate

XTRA:AAQ1

€19.3m

Audientes

DB:AUG

€6.9m

NanoRepro

XTRA:NN6

€22.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Predictive Oncology
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$4.00
52 Haftanın En Yüksek Seviyesi	US$11.66
52 Haftanın En Düşük Seviyesi	US$4.00
Beta	1.49
11 Aylık Değişim	0%
3 Aylık Değişim	-17.36%
1 Yıllık Değişim	-51.87%
33 Yıllık Değişim	-85.82%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-97.91%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	S1K	DE Medical Equipment	DE Pazar
7D	0%	-3.7%	-1.9%
1Y	-51.9%	6.6%	12.3%

Getiri vs. Endüstri: S1K geçen yıl % 8.3 oranında getiri sağlayan German Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: S1K geçen yıl % 13.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is S1K's price volatile compared to industry and market?
S1K volatility
S1K Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: S1K hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: S1K 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2002	33	Raymond Vennare	www.predictive-oncology.com

Predictive Oncology Inc. Temel Bilgiler Özeti

Predictive Oncology'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
S1K temel i̇stati̇sti̇kler
Piyasa değeri	€22.57m
Kazançlar(TTM)	-€23.03m
Gelir(TTM)	€1.28m

17.7x

P/S Oranı

-1.0x

F/K Oranı

S1K aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
S1K gelir tablosu (TTM)
Gelir	US$1.43m
Gelir Maliyeti	US$515.80k
Brüt Kâr	US$914.98k
Diğer Giderler	US$26.70m
Kazançlar	-US$25.79m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-6.44
Brüt Marj	63.95%
Net Kâr Marjı	-1,802.42%
Borç/Özkaynak Oranı	0%

S1K uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

S1K Stoklara Genel Bakış

Ödüller

Risk Analizi

Predictive Oncology Inc. Rakipler

XTRA:GME

€20.2m

XTRA:AAQ1

€19.3m

DB:AUG

€6.9m

XTRA:NN6

€22.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Predictive Oncology Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Marketplace Rule 5550(a)(2)

Predictive Oncology Inc. Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

Predictive Oncology Inc. Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development

Predictive Oncology Inc. to Report Q2, 2024 Results on Aug 14, 2024

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Recent updates

Predictive Oncology Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Marketplace Rule 5550(a)(2)

Predictive Oncology Inc. Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

Predictive Oncology Inc. Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development

Predictive Oncology Inc. to Report Q2, 2024 Results on Aug 14, 2024

Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Inc. Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Predictive Oncology Inc. has filed a Follow-on Equity Offering in the amount of $3.696 million.

Predictive Oncology Inc. to Report Q1, 2024 Results on May 15, 2024

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Predictive Oncology Inc. to Report Q3, 2023 Results on Nov 14, 2023

Predictive Oncology Inc. Announces Executive Changes

Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Predictive Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

Predictive Oncology Inc. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in FY 2021)

Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer

Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Board

Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company's Scientific Advisory Board

Predictive Oncology Appoints Matthew J. Hawryluk Ph.D. to the Board of Directors

Third quarter 2022 earnings released: US$0.052 loss per share (vs US$0.083 loss in 3Q 2021)

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Appoints David S. Smith to the Company's Board of Directors

Predictive Oncology Appoints Raymond F. Vennare as Chief Executive Officer Effective November 1, 2022

Predictive Oncology Inc., Annual General Meeting, Dec 01, 2022

Predictive Oncology Inc. Announces Retirement of J. Melville (“Mel”) Engle as Chairman and A Member of Board of Directors

Second quarter 2022 earnings released: US$0.075 loss per share (vs US$0.05 loss in 2Q 2021)

Predictive Oncology Inc. Announces Unaudited Consolidated Impairment Charges for the Three Months Ended June 30, 2022

Predictive Oncology Appoints Julia Kirshner as Chief Scientific Officer, Effective August 1, 2022

Predictive Oncology Inc. Announces Christina Jenkins Intends to Resign as Director, Effective August 31, 2022

Insider recently bought €59k worth of stock

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings released: US$0.051 loss per share (vs US$0.11 loss in 1Q 2021)

Predictive Oncology Inc. Appoints Theresa Ferguson as Senior Director of Marketing

Full year 2021 earnings released: US$0.36 loss per share (vs US$2.21 loss in FY 2020)

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Inc. Reports Strong Results from Its AA Cancer Drug Evaluation

High number of new directors

Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million.

Third quarter 2021 earnings released: US$0.083 loss per share (vs US$0.46 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.36 loss in 2Q 2020)

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.93 loss in 1Q 2020)

Director has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$6.86 loss in FY 2019)

Predictive Oncology’S, Skyline Medical Division, Developing Generation 3 Direct-To-Drain Automated Fluid Waste Management System

Predictive Oncology Inc. Completes Key Data Generation Milestones in Its Retrospective Study

Predictive Oncology Inc. announced that it expects to receive $17.635344 million in funding

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $7.389004 million.

New 90-day high: €1.30

Predictive Oncology Announces the Start of Its Drug Repurposing Project Using Its Ground-Breaking Pedal™ Platform for Ovarian Cancer

Predictive Oncology Regains Compliance with Nasdaq Minimum Bid Price Requirement

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $4.097964 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $2.2 million.

New 90-day high: €0.89